Business
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway - - Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90% - - Bolstered leadership team with appointment of John Bencich as Chief Financial Officer - IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company
About this update from Aeon Biopharma, Inc.
[{"type":"image","alt":"AEON Biopharma Inc","displaySize":"","headline":null,"caption":"AEON Biopharma Inc","className":"","disableSlideshowImg":false,"size":{"original":{"width":132,"height":32,"url":"https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7DDSqhC8eFJz3b_vK.hWvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUx/https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5","width":132,"height":32},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/7DDSqhC8eFJz3b_vK.hWvQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTUx/https://media.zenfs.com/en/globenewswire.com/a19efd6bbb6fc208e65cef7e4f3708c5","width":132,"height":32}},"lazy":false},{"type":"text","content":"- Reported positive FDA Type 2a meeting supporting ABP-450’s comparative analytical strategy under the 351(k) regulatory pathway -","length":130,"tagName":"p"},{"type":"text","content":"- Strengthened balance sheet through financing transactions and Daewoong note exchange, reducing outstanding debt by more than 90% -","length":132,"tagName":"p"},{"type":"text","content":"- Bolstered leadership team with appointment of John Bencich as Chief Financial Officer -","length":89,"tagName":"p"},{"type":"text","content":"IRVINE, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic use to achieve full-label U.S. market entry, reported today its financial results for the first quarter ended March 31, 2026, and provided a corporate update.","length":386,"tagName":"p"},{"type":"text","content":"“During the first quarter, we made meaningful progress advancing the ABP-450 development program and strengthening the company’s financial position,” commented Rob Bancroft, President and Chief Executive Officer of AEON. “We believe feedback from our BPD Type 2a meeting with the FDA supports our analytical similarity strategy under the 351(k) pathway and provides greater clarity on the path forward. In addition, the completion of our recent financing transactions, including the exchange of Daewoong-held notes, significantly reduced our outstanding debt.”","length":560,"tagName":"p"},{"type":"text","content":"“With this foundation in place, we are focused on executing ...